Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
332 stopped studies mapped to Pancreatobiliary Carcinoma and descendants · 93% state a reason
Over the 332 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04270929 | Pressure Enabled Drug Delivery By Pancreatic Retrograde Venous Infusion For Advanced…(PANC-001) | Phase 1 | withdrawn | Feb 17, 2020 | Roger Williams Medical Center | Insufficient accrual rate | Enrollment / accrual |
| NCT03536182 | Trial of Carbon Ion Versus Photon Radiotherapy for Locally Advanced, Unresectable…(CIPHER) | Phase 3 | withdrawn | May 24, 2018 | University of Texas Southwestern Medical Center | Due to COVID and other recruitment issues the trial could not be initiated. | COVID-19 / pandemic |
| NCT02608229 | BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer | Phase 1 | terminated | Nov 18, 2015 | Washington University School of Medicine | Adverse events | Safety / toxicity |
| NCT03137706 | Characterization of Mechanical Tissue Properties in Patients With Pancreatic, Liver, or… | — | terminated | May 3, 2017 | University of Southern California | Insufficient accrual | Enrollment / accrual |
| NCT03649035 | Eus-guided Cryothermal Ablation in Stage III Pancreatic Adenocarcinoma | Phase 3 | withdrawn | Aug 28, 2018 | Istituto Clinico Humanitas | Stopped for internal decisions | Other (stated, no rule matched) |
| NCT01206296 | Adjuvant Intraperitoneal Gemcitabine for Resectable Pancreatic Adenocarcinoma | Phase 2 | terminated | Sep 21, 2010 | Medstar Health Research Institute | Study suspended | Other (stated, no rule matched) |
| NCT04398927 | Systemic Chemotherapy Plus PD-1 for Metastasis ICC | Phase 2 | withdrawn | May 22, 2020 | Sun Yat-sen University | no patient enrolled | Enrollment / accrual |
| NCT03760614 | A Study of Entinostat and FOLFOX in Subjects With Pancreatic Adenocarcinoma | Phase 1 | withdrawn | Nov 30, 2018 | Abramson Cancer Center at Penn Medicine | Lack of Funding | Funding |
| NCT03563352 | Nutritional Preferences and Product Accessibility in Oral Nutritional Supplements in… | — | withdrawn | Jun 20, 2018 | University of Southern California | Zero accrual | Enrollment / accrual |
| NCT01562899 | A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors | Phase 1 / Phase 2 | terminated | Mar 26, 2012 | Pfizer | Study was withdrawn due to scientific and business considerations. | Sponsor / business decision |
| NCT03042780 | FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas | Phase 2 | terminated | Feb 3, 2017 | H. Lee Moffitt Cancer Center and Research Institute | Slow accrual | Enrollment / accrual |
| NCT04262388 | A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab…(DOME) | Phase 2 | withdrawn | Feb 10, 2020 | University Health Network, Toronto | Overall clinical activity (ORR) for oleclumab + durvalumab is minimal across tumor types and does… | Other (stated, no rule matched) |
| NCT02757391 | CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic… | Phase 1 | terminated | May 2, 2016 | M.D. Anderson Cancer Center | Study halted prematurely and will not resume; participants are no longer being examined or… | Other (stated, no rule matched) |
| NCT02012231 | Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in… | Phase 1 | terminated | Dec 16, 2013 | Fore Biotherapeutics | not stated | Not stated |
| NCT03925428 | Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and… | Phase 1 | withdrawn | Apr 24, 2019 | National Cancer Institute (NCI) | Other - Protocol moved to Disapproved | Other (stated, no rule matched) |
| NCT03890198 | A Phase 1 Study of LCAR-C182A Cells in the Treatment of Advanced Gastric Cancer and… | Early Phase 1 | terminated | Mar 26, 2019 | First Affiliated Hospital Xi'an Jiaotong University | the Preliminary data, progress of this study and the adjustment of the pipeline and strategy . | Sponsor / business decision |
| NCT01092689 | The Role of Meat-borne Carcinogens in Pancreatic Cancer | Phase 1 | withdrawn | Mar 25, 2010 | University of Minnesota | Needed New IND per FDA | Other (stated, no rule matched) |
| NCT03801499 | Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma | Phase 2 | withdrawn | Jan 11, 2019 | Sun Yat-sen University | Protocol modification | Other (stated, no rule matched) |
| NCT01333124 | Preoperative Chemoradiotherapy With Gemcitabine for Resectable Pancreatic Carcinoma | Phase 2 | terminated | Apr 11, 2011 | National Cancer Center, Korea | Recruitment delay | Enrollment / accrual |
| NCT03172832 | A Trial of Percutaneous vs. Endoscopic Drainage of Suspected Klatskin Tumors(INTERCPT) | N/A | terminated | Jun 1, 2017 | Medical University of South Carolina | Slow accrual; recommended by DSMB. | Enrollment / accrual |
| NCT04058964 | Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer | Phase 2 | withdrawn | Aug 16, 2019 | M.D. Anderson Cancer Center | Study withdrawn by supporter | Other (stated, no rule matched) |
| NCT03277209 | To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on… | Phase 1 | terminated | Sep 8, 2017 | Weill Medical College of Cornell University | terminated due to slow accrual | Enrollment / accrual |
| NCT03267940 | Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab… | Phase 1 | terminated | Aug 31, 2017 | Halozyme Therapeutics | Sponsor decision | Sponsor / business decision |
| NCT04134468 | MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma | Phase 2 | withdrawn | Oct 22, 2019 | Abramson Cancer Center at Penn Medicine | Halozyme halted development of PEGPH20 following Phase 3 failure. | Other (stated, no rule matched) |
| NCT02743975 | Near-infrared Image Guided Surgery in Pancreatic Adenocarcinoma(PENGUIN) | Phase 1 / Phase 2 | terminated | Apr 19, 2016 | University Medical Center Groningen | Insufficient tumor-to-background ratios in the first three dose groups | Other (stated, no rule matched) |
| NCT03865563 | Selective Transvenous Chemoembolization of Primary Pancreatic Tumors | Phase 1 | withdrawn | Mar 7, 2019 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | We need to make significant adjustments to proposed drug and its delivery method | Other (stated, no rule matched) |
| NCT01431794 | Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for… | Phase 1 / Phase 2 | terminated | Sep 12, 2011 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Study was terminated due to cease in manufacturing of study drug. | Drug supply |
| NCT00728000 | Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic… | Phase 2 | withdrawn | Aug 5, 2008 | University of Cincinnati | study withdrawn due to lack of enrollment | Enrollment / accrual |
| NCT03211169 | Comparison Bile Duct Brushings, Cholangioscopy-Directed Biopsies and Pediatric Forceps… | N/A | terminated | Jul 7, 2017 | Stanford University | Inadequate enrollment | Enrollment / accrual |
| NCT01413087 | Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced…(LAPC-BC-819) | Phase 2 | terminated | Aug 10, 2011 | Anchiano Therapeutics Israel Ltd. | Due to Sponsor's decision, only 12 patients were randomized \& completed study. | Sponsor / business decision |
| NCT00416793 | Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer | Phase 2 | terminated | Dec 28, 2006 | National Cancer Institute (NCI) | Study was terminated due to poor accrual | Enrollment / accrual |
| NCT04130399 | Study of Neoadjuvent Chemotherapy Followed by SBRT in Patients With Resectable and… | Phase 2 | withdrawn | Oct 17, 2019 | Indiana University | Study is being abandoned. | Other (stated, no rule matched) |
| NCT02885727 | Durvalumab Plus "Booster" RT for Metastatic Adenocarcinoma Pancreas Cancer Post…(Panc-Durval+RT) | Phase 2 | withdrawn | Aug 31, 2016 | University of Maryland, Baltimore | Funding issues caused the study to not be opened the at local IRB | Funding |
| NCT02082522 | Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar… | Phase 3 | terminated | Mar 10, 2014 | Concordia Laboratories Inc. | Accrual rate remaining too low | Enrollment / accrual |
| NCT02352831 | Tosedostat With Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma | Phase 1 / Phase 2 | terminated | Feb 2, 2015 | Washington University School of Medicine | Insufficient funding and drug supply from manufacturer | Drug supply |
| NCT03481920 | A Trial of PEGPH20 in Combination With Avelumab in Chemotherapy Resistant Pancreatic… | Early Phase 1 | terminated | Mar 29, 2018 | PH Research, S.L. | Stopped Enrollment | Enrollment / accrual |
| NCT00478140 | Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer… | Phase 2 | terminated | May 24, 2007 | National Cancer Institute (NCI) | Due to slow accrual | Enrollment / accrual |
| NCT02707328 | Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With… | Phase 1 | terminated | Mar 14, 2016 | The Cooper Health System | Closed after being on administrative hold | Other (stated, no rule matched) |
| NCT01739439 | Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance… | Phase 1 | terminated | Dec 3, 2012 | Fox Chase Cancer Center | Slow accrual | Enrollment / accrual |
| NCT02404363 | Safety and Efficacy of Clopidogrel in Locally Advanced and Metastatic Pancreatic…(PANCREADOGREL) | Phase 3 | terminated | Mar 31, 2015 | Assistance Publique - Hôpitaux de Paris | recruitment problem | Enrollment / accrual |
| NCT03778879 | Pre-operative Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma With or… | Phase 1 / Phase 2 | withdrawn | Dec 19, 2018 | Alan Katz | CCX872-B will not be available in sufficient quantity to conduct the study. | Other (stated, no rule matched) |
| NCT02955771 | Efficacy and Safety Study of PDT Using Deuteporfin for Unresectable Advanced Perihilar… | Phase 2 | terminated | Nov 4, 2016 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Business Decision | Sponsor / business decision |
| NCT02124369 | Pancreatic Resectability in Cancers With Known Limited Extension (PRICKLE)(PRICKLE) | Phase 2 | terminated | Apr 28, 2014 | CCTU- Cancer Theme | Poor accrual | Enrollment / accrual |
| NCT01313416 | Gemcitabine and CT-011 for Resected Pancreatic Cancer | Phase 2 | terminated | Mar 11, 2011 | Augusta University | Drug supply issues | Drug supply |
| NCT02736578 | Cetuximab-IRDye 800CW and Intraoperative Imaging in Finding Pancreatic Cancer in Patients… | Phase 2 | terminated | Apr 13, 2016 | Eben Rosenthal | Logistics | Other (stated, no rule matched) |
| NCT03697239 | High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin +… | Phase 1 / Phase 2 | withdrawn | Oct 5, 2018 | Hitendra Patel | FDA indicated the same study could not be conducted under multiple INDs | Other (stated, no rule matched) |
| NCT03432676 | Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer | Phase 2 | withdrawn | Feb 14, 2018 | M.D. Anderson Cancer Center | Incyte (supporter of the study) is no longer going to support the study. | Other (stated, no rule matched) |
| NCT03908333 | High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and… | Phase 1 / Phase 2 | withdrawn | Apr 9, 2019 | Medical College of Wisconsin | Request to close per funding sponsor. Site not moving forward with trial. | Funding |
| NCT02950025 | Daily Online Adaptation Versus Localization for MRI-Guided SBRT for Unresectable Primary… | Phase 2 | terminated | Oct 31, 2016 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT02782182 | Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot… | Phase 1 | terminated | May 25, 2016 | University of Chicago | Closed early due to poor accrual. | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jun 1, 2021source: clinicaltrials